

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Draper *et al.* CONFIRMATION No.: 9127
APPLICATION NO.: 10/692,563 EXAMINER: Sabiha Naim Qazi
FILING DATE: October 24, 2003 ART UNIT: 1612
FOR: SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA

VIA EFS**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

Applicants note that the references included herewith were cited in the corresponding Japanese application. Applicants were notified of these references on December 17, 2008.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: **Draper et al.**
U.S.S.N.: **10/692,563**

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 16534-526002US.

Respectfully submitted,

A handwritten signature in cursive script that reads "Christopher E. Olson".

Heidi A. Erlacher, Reg. No. 45,409
Christopher E. Olson, Reg. No. 55,510
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

ACTIVE 4632654v.1